Related references
Note: Only part of the references are listed.Examining the Potential Impact of Race Multiplier Utilization in Estimated Glomerular Filtration Rate Calculation on African-American Care Outcomes
Salman Ahmed et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2021)
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Paul M. Ridker et al.
CIRCULATION RESEARCH (2021)
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Paul M. Ridker et al.
LANCET (2021)
Adverse Effects of Low-Dose Methotrexate A Randomized Trial
Daniel H. Solomon et al.
ANNALS OF INTERNAL MEDICINE (2020)
Methotrexate and its mechanisms of action in inflammatory arthritis
Bruce N. Cronstein et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Adverse Effects of Low-Dose Methotrexate
R. Brooks Robey et al.
ANNALS OF INTERNAL MEDICINE (2020)
Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial
Jeffrey A. Sparks et al.
ARTHRITIS & RHEUMATOLOGY (2020)
International consensus definitions of clinical trial outcomes for kidney failure: 2020
Adeera Levin et al.
KIDNEY INTERNATIONAL (2020)
Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial
Kathleen M. M. Vanni et al.
ACR OPEN RHEUMATOLOGY (2020)
Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis
Keigo Hayashi et al.
SCIENTIFIC REPORTS (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
Lesley A. Inker et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
Paul M. Ridker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Rheumatoid arthritis
Josef S. Smolen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study
Jeffrey A. Sparks et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Brendan M. Everett et al.
AMERICAN HEART JOURNAL (2013)
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
Paul E. Stevens et al.
ANNALS OF INTERNAL MEDICINE (2013)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Use of mycophenolic acid in non-transplant renal diseases
Patricia M. Stassen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2006)
Understanding and managing methotrexate nephrotoxicity
Brigitte C. Widemann et al.
ONCOLOGIST (2006)
Methotrexate causes oxidative stress in rat kidney tissues
E Devrim et al.
RENAL FAILURE (2005)
Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats
N Jahovic et al.
JOURNAL OF PINEAL RESEARCH (2003)
Share Paper
